InvestorsHub Logo
icon url

gfp927z

04/13/12 12:20 PM

#38226 RE: neuroinv #38224

Neuro, Thanks for the update.


>>> Les Street left for an academic position at the University of Capetown <<<


Can't say I blame him for leaving, but it's a major loss for Cortex. While Dr. Rogers laid the foundation, Dr. Street created all the new Ampakine compound families, pretty much everything after CX-717.















icon url

atheroprevent

04/13/12 3:00 PM

#38229 RE: neuroinv #38224

Thanks for the input, Neuro. We seem to be trapped in a fog (maybe a different version of the trapped longs Jerry referred to a while back).

Hard to gauge the impact of the law suits in France. I agree they could be negatively impacting Servier's R+D strategy.

Here it seems to be, unfortunately, part of routine pharmaceutical business. J&J will be appealing their 1.1B Risperdal judgement and I think some of their executives are still at risk with the Tylenol shenanigans. Most of the BP's here, have had significant suits. Looks like the contagion is spreading to Europe. New drugs need to be squeaky clean, otherwise they will be sucked into the quagmire.

Who could have forseen that Risperdal would be found faulty, based on weight gain-->diabetes-->vascular disease after longterm use. Perhaps, the lawyers should sue the USDA, instead, or whoever created the food pyramid, fueling obesity, because the carbohydrates and grains at the base might need to be more restricted than fats and protein at the apex of the pyramid.
icon url

jerrydylan

04/17/12 2:50 PM

#38265 RE: neuroinv #38224

Before the $2 million came in, it was a concern that this would prevent Servier from taking the US rights, per conversations.